Invesco DB Agriculture Fund vs Revvity Inc — how do they compare? Invesco DB Agriculture Fund trades at $27.74, while Revvity Inc trades at $116.35 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while Invesco DB Agriculture Fund pays none, and Revvity Inc is trading nearer its 52-week high, Invesco DB Agriculture Fund nearer its low. Which is the better fit depends on your goals.
| DBA | RVTY | |
|---|---|---|
52-Week High | $28.73 | $117.75 |
52-Week Low | $25.44 | $82.26 |
Market Cap | — | $12.91B |
Sector | — | Technology |
Enterprise Value | — | $15.23B |
Dividend Yield | — | 0.24% |
Signals from Pluang's Aura AI — not financial advice
DBA trades at $27.69, down 0.47% today, but maintains a strong technical bullish signal with moving averages indicating positive momentum. The fund has outperformed the S&P 500 recently, gaining 5% in July 2026, driven by strength in agricultural commodities. It consolidates near highs with a bullish trend established since 2020, supported by a 3.25% yield.
The outlook remains positive given favorable agricultural market dynamics and geopolitical factors supporting commodity prices. Key risks include sector volatility, management fees, and sensitivity to global crop conditions and trade policies. The fund offers diversified exposure to agricultural futures as a hedge against inflation and supply disruptions.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Trailing returns across standard periods
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →